



PHARMACEUTICAL 2017









PHARMACEUTICAL 2017



Xencor Inc Rank 23 of 313



The relative strengths and weaknesses of Xencor Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xencor Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 217% points. The greatest weakness of Xencor Inc is the variable Revenues, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is 162%, being 578% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	141,653
Cost of Goods Sold	0
Intangible Assets	10,362
Liabilities, Current	106,286
Liabilities, Non-Current	0
Other Assets	273,443
Other Compr. Net Income	-925
Other Expenses	991
Other Liabilities	8,323
Other Net Income	89,596
Property and Equipment	3,105
Research and Development	51,872
Revenues	0
Selling, General and Administrative Expense	13,108

Output Variable	Value in 1000 USD
Assets	428,563
Liabilities	114,609
Expenses	65,971
Stockholders Equity	313,954
Net Income	23,625
Comprehensive Net Income	23,162
Economic Capital Ratio	162%